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A B S T R A C T
The objective of this work was to develop a new protocol to predict with greater confidence peptides as potential
inhibitors of the renin enzyme. For this, free, friendly and rigorous servers developed specifically for peptides as
ligands were used. Six peptides (SFNLPILR; FNLPILR; SFNLPIL; QAFEDGFEWVSFK; AFEDGFEWVSFK and
VNVDDPSKA) identified in an amaranth hydrolysate obtained with alcalase (hydrolysis degree 21%±4) were
used. Two positive (angiotensinogen and IRLIIVLMPILMA) and one negative (a tridecapeptide of alanine)
controls were included in the analysis. A protocol was designed to include two consecutive stages was performed
using CABS-dock server (http://biocomp.chem.uw.edu.pl/CABSdock) and FlexPepDock server (http://
flexpepdock.furmanlab.cs.huji.ac.il/). Peptides SFNLPILR, FNLPILR and AFEDGFEWVSFK inhibited the en-
zyme in vitro. The heptapeptide FNLPILR was the most potent inhibitor, with an IC50 of 0.41 mM.
1. Introduction
In mammals, blood pressure (BP) is regulated by the renin angio-
tensin aldosterone system through two main enzymes: renin and an-
giotensin converting enzyme (ACE) (Zhou et al., 2017). The first drugs
developed for the control and regulation of BP focused on inhibition of
ACE and in blocking receptors that interact with angiotensin II, the
product released by this enzyme. However, renin inhibition would be a
better target to control BP since this enzyme acts on a single substrate,
in the first step of enzymatic cascade thus controlling the rate of the
reaction that triggers the increase in BP (Duprez, 2006). Nevertheless,
the development of renin inhibitors has not been as successful because
they are not effective in inhibiting the enzyme in vivo. Until now only
one effective inhibitor of renin has been developed (aliskiren,
IC50 = 0.6 nM) (Wood et al., 2003).
In addition to pharmacological treatment, one of the strategies used
to reduce BP is to encourage changes in habits, for example, by in-
corporating into diet ingredients that contribute to preserving and
maintaining health. Bioactive peptides generated during processing and
preparation of food or generated from gastrointestinal digestion of food
proteins are products that have been widely studied, especially in terms
of their antihypertensive effect. The studies related with anti-
hypertensive peptides derived from food sources focused on the pos-
sible action on ACE, and also on renin inhibition (Aluko, 2019; Pihlanto
& Mäkinen, 2017).
Amaranth, an Andean crop with high quality proteins, has been
studied as a source of bioactive peptides (Orsini Delgado et al., 2016;
Quiroga, Barrio, & Añón, 2015; Sabbione, Nardo, Añón, & Scilingo,
2016; Tovar-Pérez, Lugo-Radillo, & Aguilera-Aguirre, 2018). Particu-
larly the antihypertensive activity of amaranth peptides has been stu-
died both in vitro and in vivo, assays in which it has been demonstrated
that they act on ACE plasma, renin plasma and the vascular system
(Aphalo, Martínez, & Añón, 2015; Barba de la Rosa et al., 2010; Fritz,
Vecchi, Rinaldi, & Añón, 2011; Quiroga, Aphalo, Ventureira, Martínez,
& Añón, 2012; Suárez, Aphalo, Rinaldi, Añón, & Quiroga, 2020; Vecchi
& Añón, 2009). In addition, these peptides have been incorporated into
different matrices such as emulsions and cookies with potential anti-
hypertensive activity (Sabbione, Suárez, Añón, & Scilingo, 2019; Suárez
& Añón, 2019). In a previous work, we identified the amino acid se-
quence of six peptides (SFNLPILR, FNLPILR, SFNLPIL, QAFEDGFEWV-
SFK, AFEDGFEWVSFK and VNVDDPSKA) in an amaranth alcalase hy-
drolysate (hydrolysis degree 21%±4) as renin inhibitors (Quiroga,
Aphalo, Nardo, & Añón, 2017).
Despite the advances in obtaining and purifying bioactive peptides,
one of the most important challenges in this area remains to identify the
most active of a set of potential active sequences. Bioinformatics and
computational chemistry have different useful tools to address this
problem. Biomolecular simulation techniques are fundamental tools to
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understand the type of molecular interactions and analyze the corre-
lation between structure-activity. However, not all simulations are
suitable or applicable to all systems, among other reasons because the
equations that support the method and/or those that were timely de-
veloped lose their validity (Bottaro & Lindorff-Larsen, 2018). Besides
the application of more rigorous simulation methods in complex sys-
tems requires a lot of time and calculation capacity.
Among the techniques of molecular simulations, molecular docking
is the most used to predict the predominant binding mode of ligands
with a protein. However, its use with peptides continues to be a chal-
lenge for the scientific community (Ciemny et al., 2018; Tu, Cheng, Lu,
& Du, 2018). Many authors use docking techniques to complement their
experimental tests, because they are freely available and have been
successful with small peptides (2-4 residues), but their use with larger
sequences leads to false positives. The main difficulty of docking pep-
tides as ligands is due to peptides, even short ones, are often highly
flexible, with few rigid parts, such as double bonds or ring systems.
The main objective of this work was to test new free, friendly and
rigorous servers developed specifically for docking with peptides to
predict with greater confidence the best peptides that could act as en-
zyme inhibitors. We used six peptides that we previously identified
(Quiroga et al., 2017) to perform a docking protocol of two consecutive
stages. First, CABS-dock server was used to explore the possible sites of
interaction on renin surface, obtain the peptide-protein complexes and
analyze the residues involved in the interaction. In the second stage,
FlexPepDock server was used to estimate the energy of peptide-protein
interaction (evaluated by Rosetta score) starting from the CABS-dock
complexes where the peptide was located in the active site. We included
in the analysis as positive controls angiotensinogen (DRVYIHPFHLV-
IHN) and the peptide IRLIIVLMPILMA (IC50 = 6.5 mM) (Fitzgerald
et al., 2012) and as a negative control a tridecapeptide of alanine.
2. Materials and methods
2.1. CABS-dock server
The CABS-dock server (http://biocomp.chem.uw.edu.pl/CABSdock,
accessed on February of 2019) (Kurcinski, Jamroz, Blaszczyk, Kolinski,
& Kmiecik, 2015) performs flexible protein-peptide docking. CABS-
dock automated protocol merges coarse grained simulation with all-
atom local optimization of selected reconstructed models. Starting from
crystalline structure of renin and amino acid sequence of putative li-
gands, this server perform docking search for the binding site allowing
for full flexibility of the peptide and small fluctuations of the receptor
backbone. For each peptide and controls, we use the structure PDB
2V0Z (chain C) of renin with 50 cycles of Monte Carlo simulation.
Complementary analyzes of the resulting structures were done with
VMD (Humphrey, Dalke, & Schulten, 1996).
2.2. FlexPepDock server
FlexPepDock server was employed to find high-resolution modeling
of protein-peptide interactions (London, Raveh, Cohen, Fathi, &
Schueler-Furman, 2011). This server, freely available at http://
flexpepdock.furmanlab.cs.huji.ac.il/ (accessed on February of 2019),
is based on Rosetta modeling software (version 3.2). It uses Monte Carlo
minimization approach to stabilize peptide backbone and rigid body
orientation respectively. Initially, peptide structure was refined in 200
independent FlexPepDock simulations, which included 100 stimula-
tions in high-resolution mode and 100 stimulations in low-resolution
mode with pre-optimization followed by high-resolution refinement.
Finally, FlexPepDock created 200 models for each analysis and they
were further ranked based on their Rosetta generic full atom energy
score (London et al., 2011).
The structures used for this stage of refinement were obtained from
the analysis performed with CABS-dock server. Previously, residues in
pdb file were renumbered according FlexPepDock needs. Three in-
dependent replicates were made for each peptide, specifying in 200 the
number of low resolution structures and the number of high resolution
structures. Complementary analyzes of the resulting structures were
done with VMD (Humphrey et al., 1996).
2.3. Synthetic peptides
Peptides SFNLPILR (P1), FNLPILR (P2), AFEDGFEWVSFK (P5) and
VNVDDPSKA (P6) were synthesized, HPLC purified to more than 95%
purity, and analyzed by HPLC-MS by the company ChinaPeptides Co.
Ltd. (Shanghai, China).
2.4. Renin inhibition assay
In vitro inhibition of human recombinant renin was performed with
Renin Inhibitor Screening Assay Kit (Cayman Chemical, MI, USA) ac-
cording to their instructions. Substrate and assay buffer were added to
the following wells: (a) background, (b) 100% initial activity, (c)
background peptide inhibitor sample and (d) peptide inhibitor. The
enzymatic reaction was initiated by the addition of renin to (b) and (d)
treatment wells. The microplate was shaken for 10 s and was incubated
at 37 °C for 15 min. The fluorescence intensity (FI) was then recorded
using an excitation wavelength of 340 nm and an emission wavelength
of 490 nm in a microplate reader (Biotek Synergy HT, Winooskii, VT,
USA).
The IC50 values were calculated by dose–response curves. The
logarithmic values of three (P1) or five (P2 and P5) different sample
concentrations (mg/mL) against the inhibitory activity (%) were
plotted. The IC50 values were calculated by dose–response curves using
a nonlinear regression sigmoidal curve fit functions (normalized re-
sponse) to P1 and P5 in GraphPad prism 6.01 (Graphpad Software Inc.,
San Diego, CA, USA). As for P2 we have a complete data set that defines
a sigmoidal curve, a nonlinear regression sigmoidal curve fit functions
was used.
2.5. Kinetics of renin inhibition
Preliminary studies of kinetics of renin inhibition were performed
using 2.5, 3.5, 5, and 10 µmol/L substrate in the absence and presence
of P2 at 0.25 mM and 1 mM.
3. Results and discussion
Human renin (EC 3.4.23.15) is a 335 amino acid, glycosylated as-
partic protease composed of two β-sheet domains with a cleft between
them (Pihlanto & Mäkinen, 2017; Yuan, Wu, Aluko, & Ye, 2006). The
active site is located in this cleft and is formed by distinct binding
pockets which recognize the side chains of angiotensinogen, called S1,
S2, S3, S1′ and S2′ sites, and the non-substrate S3SP (S3 subpocket) site
(Rahuel et al., 2000). Each domain provides one of the catalytic re-
sidues Asp32 and Asp215 (numbering based on the pepsin sequence),
which are located around the center of the cleft to promote the cleavage
of the Leu10–Val11 peptide bond on angiotensinogen. It has been
crystallized alone and linked to different ligands (Tawada et al., 2016).
For this study, we used the crystalline structure that has been co-crys-
tallized with aliskiren (PDB 2V0Z), the only commercial inhibitor of
this enzyme. Our research was focused on identifying the sequences
responsible for renin inhibition by an amaranth hydrolysate previously
evaluated (Quiroga et al., 2017). With this objective and taking into
account the relevance of in silico tools and bioinformatics approach on
the study of bioactive peptides, we try out new servers specifically
developed for docking peptide-protein which are friendly with experi-
mental scientists and have fast implementation.
CABS-dock server was used to perform a global docking on the
entire surface of renin, without restriction on peptide binding site. This
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docking algorithm returns, for each peptide evaluated, 10 models of the
complex peptide-protein numbered according to the cluster density,
which is the ratio of number of elements in each structural cluster, and
the backbone root mean square deviations (RMSD) of cluster members
(a measure of the structural difference). Results show that all peptides
evaluated were capable of interacting with renin through different sites
on its surface. As an example, the Fig. 1 shows the structure of corre-
sponding results obtained using P5 peptide for docking. Peptide P5
residues were located at the active site in 7 of the 10 final models
proposed. In contrast, for angiotensinogen and controls, peptides were
located at the active site only in one of the 10 final models. Table 1
summarizes the number of finals models in which peptides were docked
at the active site of renin.
As expected, we observed different binding patterns depending on
the peptide evaluated. To characterize the binding sites detected and
analyzed if they are the same for different peptides, contact profiles
were constructed. For all final models obtained, renin residues located
at a distance of 4.5 Å of each peptide were counted. These results are
shown in Fig. 2. This representation allows us to graphically analyze the
















Fig. 1. Structure of the 10 finals models generated of CABS-dock results using P5 (AFEDGFEWVSFK) as a ligand. The peptide evaluated is show in red colour.
Table1
Details of CABS-dock results.
Peptide Number of the ten finals models
docked at active site of renin
Detail of interaction with renin of model selected to refine with FlexPepDock
P1 – SFNLPILR 3 (models 1, 2, 3) and 1 near outside
(model 4)
Model 1 interacts with Asp32 and Asp215.
P2 – FNLPILR 3 (models 3, 4, 5) Model 4 shows the interaction with Asp215.
P3 – SFNLPIL 3 (models 1,2,3) Model 2 interacts with Asp32 and Asp215. The other two have no interaction with catalysts.
P4 – QAFEDGFEWVSFK 2 near outside None of the models located near of the active site interacts with catalytic residues.
P5 – AFEDGFEWVSFK 7 (models 1, 2, 5, 6, 7, 9 and 10) Model 1 and model 5. Both models interact with Asp32 and Asp215, through different
residues. They present opposite orientations in the cleft of the active site.
P6 – VNVDDPSKA 3 (models 1, 3, 8) and 2 near outside Model 3 witch interacts with Asp32 and Asp215.
Angiotensinogen – DRVYIHPFHLVIHN 1 (model 5) Model 5 witch interacts with Asp32 and Asp215.
CONTROL – IRLIIVLMPILMA 1 (model 1) Model 1 and model 9. Both models interact with Asp32 (model 1 by Arg2 and model 9 by Ile1)
and Asp215 (model 9 by Ile4 and Leu3; model 1 by Ile4 and Ile5).
CONTROL – AAAAAAAAAAAAA 1 (model 3) Model 3, shows the interaction with Asp215 by Ala13.
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profile we observe some renin residues (such as 9, 10 12 and 13; 73, 74
and 75; 240, 241 and 242; and 281, 282 and 283) which participate in
interactions in at least one model of each peptide evaluated, regardless
of its sequence. These regions could be protein-protein recognition
motifs located on renin surface.
Considering that the amaranth hydrolysate, from which our ligands
were isolated behaved as a competitive renin inhibitor (Quiroga et al.,
2017), we continued our studies with the model in which peptides were
located in the active site. Interaction energies were calculated using the
FlexPepDock server. Peptides often lack a distinct fold in their unbound
state, and go through simultaneous binding and folding upon en-
countering their target protein receptor. The docking algorithm of
FlexPepDock takes this into account and performs a high-resolution
structural and energy refinement of the peptide in the binding site. This
method has been tested in a large reference set of protein-peptide
complexes and has been shown to generate high resolution models
(London et al., 2011). This is more suitable for modeling protein-pep-
tide interactions, than a global docking protocol such as that performed
by the CABS-dock. FlexPepDock is based on coarse grained simulations
(Kmiecik et al., 2016) and needs a protein peptide complex, where the
ligand must be located at the active site of the enzyme (or interaction
site). For this reason, we started from the models generated with CABS-
dock. Table 1 also details the model selected to perform this stage,
according to the interactions observed. Peptide P4 was discarded in this
second stage because neither was docked at the active site nor in its
vicinity, probably due to steric impairments as a result of its size and/or
the lack of recognition motif in its sequence.
As an output, FlexPepDock server gave the 10 best predicted models
for each peptide-protein complex, ordered according to Rosetta score.
This score in Rosetta corresponds to weighted sums of energy terms,
some of which represent physical forces such as electrostatics and van
der Waals' interactions, while others represent statistical terms such as
the probability of finding the torsion angles in Ramachandran space
(Alford et al., 2017). In addition, if the user prefers, the output details
the value score terms, like energy on the interface, for each model.
Table 2 summarizes FlexPepDock results.
All docking performed presented positive values of Rosetta score.
This parameter is correlated with peptide-protein interaction energy
and therefore negative values are expected. The positive results ob-
tained were probably due to internal clashes in the receptor structure
(renin) that are not relieved by the classic FlexPepDock protocol, be-
cause this only optimizes the side chains on the receptor in the vicinity
of the ligand. Although much of the energy function in Rosetta is
physics-based, it also has certain statistical terms to favor structures
that look like known protein structures. A lower scoring structure is
more likely to be closer to the real/native structure. The score corre-
lates with energy, but do not have a direct conversion to physical en-
ergy units like kcal/mol. When we analyzed the different components of
the Rosetta score, the energy at the interface and the terms of peptide
scoring, were effectively negative. These values confirm that interaction
of evaluated ligands and renin was possible and favorable, although the
overall score are positive. This highlights the “problem of scoring
function” of docking methods (Meng, Zhang, Mezei, & Cui, 2011;
Rentzsch & Renard, 2015). FlexPepDock requires a “good” complex
(peptide-receptor) to perform energy refinement. Taking this into
consideration, to verify that positive scores were due to structural
problems, as internal clashes of laterals chains of renin, in the starting
structure, we performed new dockings of each peptide and controls. In
this case we performed stage of energy minimization using NAMD with
force field CHARMM27. After that, a decrease in Rosetta scores was
observed, but they still showed values greater than zero.
Considering that the main objective of this study was to identify
from the list of six peptides which ones were the best renin inhibitors,
we proceeded to select peptides to be synthesized for in vitro evaluation
based on all results found in both global and local docking. Peptides P1
(SFNLPILR) and P5 (AFEDGFEWVSFK) were synthesized because they
presented the best interaction energy with renin according to
FlexPepDock and both have the highest number of models coupled to
the active site according to CABS-dock results. To validate the pre-
dictive value of protocols used in this study, P2 (FNLPILR) and P6
(VNVDDPSKA) were also synthesized.
Experiments performed with the synthetic peptides confirmed that,
three of the four peptides synthesized interact with renin and modulate
its activity. Fig. 3 shows the percentage of renin inhibition caused by
different concentrations of P1, P2 and P5. These peptides inhibited the
enzyme in a dose response manner, IC50 values are shown in the table
ASP 32 ASP 215 
P1 - SFNLPILR 
P2 - FNLPILR 





Fig. 2. Number of contacts (pairs of peptide/receptor residues closer than 4.5 Å) of the 10 finals models of peptide-renin generated by CABS-dock as a function of
renin residue. The catalytic residues Asp32 and Asp215 are marked with black lines.
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inserted in Fig. 3. P2 was the most potent inhibitor with an IC50 equal to
0.41 mM, while P6 was inactive at all concentrations tested. These
results did not totally agree with score values obtained with FlexPep-
Dock, which predicted a higher affinity for P1 followed by P5 and P2.
This inaccuracy has been reported by other authors (Lammi, Zanoni,
Aiello, Arnoldi, & Grazioso, 2016), although in many cases the results
are not published and reflect the problem of scoring function that
docking techniques have in common (Bottaro & Lindorff-Larsen, 2018).
Peptide P2 has a better IC50 value than other reported renin-in-
hibitory peptides from different food sources as pea protein hydro-
lysate, microalgae palmaria palmata, rapeseed and flaxseed (Fitzgerald
et al., 2012; García-Mora et al., 2017; He, Malomo, Girgih, Ju, & Aluko,
2013; Li & Aluko, 2010).
Based on these results, the kinetics of renin inhibition was studied
for P2 to elucidate the mechanism of action (Fig. 4). Although results
are preliminary, this peptide behaved as a competitive inhibitor of the
enzyme. While some of the reported peptides interact with the active
site as mixed inhibitors, most peptides reported in the literature are
noncompetitive suggesting the existence of other sites on the enzyme
that could interact with inhibitory peptides and modulate their activity
through conformational changes. Usually, human angiotensinogen is
represented only with its 14 N-terminal (the segment which is re-
cognized by renin) but it is a 485 amino acid protein. This simplifica-
tion is useful in different studies, like ours, but it should be noted that
the recognition mechanism between both molecules is somewhat more
complex and probably is mediated by the association of angiotensi-
nogen with renin outside the active cleft. To confirm this behavior we
need to analyze a higher number of substrate and peptide concentra-
tions.
Fig. 5A shows the best poses of peptides and controls performed
with CABS-dock. For P1, P2 and P5 Fig. 5B details the structure of
renin-peptide complex and includes 2D diagrams of interactions of
amaranth peptides with renin residues corresponding to the best Flex-
PepDock pose. Although P1 and P2 differ only in one residue, according
the docking studies performed they adopt different orientation to in-
teract with renin. While P1 orients its N-terminal towards catalytic
residues, P2 interacts through the R residue located at its C-terminal. P2
mainly establishes two hydrogen bonds, one by the amino group of the
side chain of R residue with the acid group of Glu103 of renin, and
another through the α-amino of L with the carboxyl of Asp215 of renin.
Also contribute to the interaction a π-interaction through side chain of
the L residue and Tyr75 of renin. On the other hand, the dodecapeptide
P5 adopts a turn conformation, and directs its residue W towards the
catalytic residues. This agree with Udenigwe, Li, and Aluko (2012) who
previously reported that the most potent dipeptide predicted by QSAR
analysis have a W residue at C-terminal. Although P5 (AFEDGFEWV-
SFK) and P1 (SFNLPILR) contain in their sequence the SF motif, re-
ported as a renin inhibitor by Udenigwe et al. (2012), it seems that in a
greater amino acid sequence as in P5 the preference of renin pre-
dominates for bulky amino acids as W. It is probably the existence of a
major structural restriction of recognition. Finally, the difference in
activity between P1 and P2 is probably due to the specific orientation
that both peptides adopt at the renin active site; while P1 interacts by
SF motif, P2 do it by LR motif. This agree with the values of renin
inhibition reported by Udenigwe et al. (2012) when they evaluated
these sequences as dipeptides.
4. Conclusion
In this work we have identified a heptapeptide (FNLPILR) as an
inhibitor of the renin enzyme, demonstrating that amaranth proteins
contain encrypted different sequences capable of inhibiting renin in
vitro. CABS-dock server was used as a first approximation to generate
the peptide-renin complex and identify those sites most likely to in-
teract. FlexPepDock server was used to refine the interaction energy of
the complex. We introduced and discussed the application of adequate
free software to use in the identification of bioactive peptides with some
Table 2
Description of FlexPepDock results.
Peptide FlexPepDock with CABS-dock models FlexPepDock with CABS-dock models after energy minimization of the complex
Rosetta Score Interface energy Rosetta Score Interface energy
P1 – SFNLPILR Model 1 1074 ± 22 −13 ± 2 246 ± 1 −18 ± 1
P2 – FNLPILR Model 4 1341 ± 10 −12.7 ± 0.4 358 ± 4 −14 ± 3
P3 – SFNLPIL Model 2 1177 ± 2 −15.5 ± 0.2 255 ± 2 −12.1 ± 0.4
P5 – AFEDGFEWVSFK Model 1 1336 ± 4 −15 ± 0.5 331 ± 4 −19 ± 3
P5 – AFEDGFEWVSFK Model 5 1072 ± 11 −22 ± 4 267 ± 0.1 −25 ± 2
P6 – VNVDDPSKA Model 3 1254 ± 21 −18 ± 1 317 ± 5 −20 ± 1
Control – IRLIIVLMPILMA Model 9 1110 ± 21 −13 ± 2 281 ± 1 −25.6 ± 0.4
Control – Angiotensinogen Model 5 1160 ± 23 −24 ± 7 375 ± 6 −30.5 ± 0.3
Peptide concentration (mM)









P1 - SFNLPILR 2.50
P2 - FNLPILR 0.41










Fig. 3. Renin inhibitory activity of peptides analyzed. P1: SFNLPILR, P2:
FNLPILR and P5: AFEDGFEWVSFK. P6 showed no activity in range tested
(0.13–2.90 mM). Inset table: IC50 values (mM) of peptides assayed.










control P2 (0.25 mM) P2 (1mM)
Fig. 4. Kinetics of renin inhibition by P2 (FNLPILR) at varying concentrations
of renin substrate (2.5–10.0 μM).
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Fig. 5. A. Structural alignment of renin complexes with peptides obtain by CABS-dock server. Peptides P1, P2, P3, P4, P5, P6 and controls are shown in the color scale
detail in the same figure. B. Conformation details at the active site of renin for P1, P2 and P5. The complexes are shown in three different ways for each peptide. In the
first, molecular surface of renin is represented in cyan color. The second is the same structure without the surface. The third one is a 2D diagram chemical structure of
P1, P2 and P5 and binding pockets of renin corresponding to the interaction observed on the best FlexPepDock model. Due to software restrictions, P5 structure is
represented without its first residue (Ala) and is indicated by an arrow with an asterisk where it should be. This residue is located completely outside of renin active
structure.
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additional advantages: fast implementation and friendly with experi-
mental scientists. Recently CABS-dock incorporates new extensions for
adding a refinement step and a stand-alone version (available at
https://bitbucket.org/lcbio/cabsdock/src/master/). These improve-
ments can probably result in an increase in the success rates of this
docking protocol with bioactive peptides from food proteins.
By far docking with peptides remains to be a challenge for the sci-
entific community, and this is a trend area of bioinformatics. The
protocol used in this work employs new servers specifically developed
for this purpose. However, we must also be pragmatic in the way bio-
molecular simulations are used. Like experiments, simulations are not
perfect; the analysis of results often requires specialized knowledge and
its use without in vitro validation can lead to uncertain results.
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